Skip to main content
. 2021 Jan 28;124(7):1187–1198. doi: 10.1038/s41416-020-01224-6

Fig. 3. Hyperpolarised 13C-MRI in a patient with metastatic prostate cancer.

Fig. 3

Hyperpolarised 13C-MRI in a patient with metastatic prostate cancer undergoing androgen deprivation therapy before and after 6 weeks of treatment initiation.69 Representative axial T2-weighted (T2W) anatomic image and corresponding apparent diffusion coefficient (ADC) image, T2W image with an overlaid pyruvate-to-lactate metabolic exchange rate (kPL) image and corresponding hyperpolarised 13C spectral array are shown. The 52-year-old prostate cancer patient with extensive high-grade prostate cancer was imaged a before therapy and b 6 weeks after initiation of androgen ablation and chemotherapy. Before treatment, the region of prostate cancer can be clearly seen (red arrows) as a reduction in signal on the T2W and ADC images, and increased hyperpolarised lactate and associated kPL on hyperpolarised 13C-MRI. After initiation of androgen deprivation therapy there was a significant reduction in hyperpolarised lactate and kPL to normal levels, with the prostate volume and ADC showing only a modest response to treatment. Reprinted from European Urology, volume 72, Aggarwal, R., Vigneron, D. B. & Kurhanewicz, J., Hyperpolarized 1-[13C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer, pages 1028–1029, Copyright (2017), with permission from Elsevier.